The Multiple System Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Multiple System Atrophy Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Multiple System Atrophy Market.
Some of the key takeaways from the Multiple System Atrophy Pipeline Report:
- Companies across the globe are diligently working toward developing novel Multiple System Atrophy treatment therapies with a considerable amount of success over the years.
- Multiple System Atrophy companies working in the treatment market are Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd., Selecta Biosciences Inc, and others, are developing therapies for the Multiple System Atrophy treatment
- Emerging Multiple System Atrophy therapies in the different phases of clinical trials are- NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, and others are expected to have a significant impact on the Multiple System Atrophy market in the coming years.
- In May 2023, Ampreloxetine has been given OrphanDrug Designation (ODD) status by the US Food and Drug Administration (FDA) for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA).
- In March 2023, In order to address symptomatic neurogenic orthostatic hypotension in patients with Multiple System Atrophy, Theravance Biopharma started a Phase III, multicenter, randomised withdrawal and long term extension study with ampreloxetine.
Multiple System Atrophy Overview
A rare condition called multiple system atrophy (MSA) could afflict 15,000 to 50,000 Americans, including persons from all racial groups. There is no recognised cause of MSA. Most occurrences are irregular, which means they happen at random.
Get a Free Sample PDF Report to know more about Multiple System Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/multiple-system-atrophy-msa-pipeline-insight
Emerging Multiple System Atrophy Drugs Under Different Phases of Clinical Development Include:
- NM-402: Neuramedy Co.,Ltd
- PMN442: ProMIS Neurosciences
- ENT-01: Enterin Inc.
- NC-2500: Nippon Chemiphar
- CS10BR05: CORESTEM, Inc
- AAV2-GDNF: Brain Neurotherapy Bio, Inc.
- KM-819: Kainos Medicines
- ATH434: Alterity Therapeutics
- Lu AF82422: H. Lundbeck A/S
- Verdiperstat: Biohaven, Ltd.
- Ampreloxetine: Selecta Biosciences Inc
Multiple System Atrophy Route of Administration
Multiple System Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
- Inhalation
- Inhalation/Intravenous/Oral
- Intranasal
- Intravenous
- Intravenous/ Subcutaneous
- NA
- Oral
- Oral/intranasal/subcutaneous
- Parenteral
- Subcutaneous
Multiple System Atrophy Molecule Type
Multiple System Atrophy Products have been categorized under various Molecule types, such as
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Recombinant protein
- Small molecule
- Stem Cell
- Vaccine
Multiple System Atrophy Pipeline Therapeutics Assessment
- Multiple System Atrophy Assessment by Product Type
- Multiple System Atrophy By Stage and Product Type
- Multiple System Atrophy Assessment by Route of Administration
- Multiple System Atrophy By Stage and Route of Administration
- Multiple System Atrophy Assessment by Molecule Type
- Multiple System Atrophy by Stage and Molecule Type
DelveInsight’s Multiple System Atrophy Report covers around 20+ products under different phases of clinical development like
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I)
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
Further Multiple System Atrophy product details are provided in the report. Download the Multiple System Atrophy pipeline report to learn more about the emerging Multiple System Atrophy therapies
Some of the key companies in the Multiple System Atrophy Therapeutics Market include:
Key companies developing therapies for Multiple System Atrophy are – Theravance Biopharma, Ionis Pharmaceuticals, Inc., Biohaven Pharmaceuticals, Lundbeck A/S, Alterity Therapeutics, Brain Neurotherapy Bio, Inc., Biogen, Corestem, Inc., Asklepios BioPharmaceutical, Inhibikase Therapeutics, RETROTOPE, Modag, AC Immune, Vaxxinity, Neuramedy, ProMIS Neurosciences, FAScinate Therapeutics, Wren Therapeutics, Blade Therapeutics, Stealth BioTherapeutics, and others.
Multiple System Atrophy Pipeline Analysis:
The Multiple System Atrophy pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Multiple System Atrophy with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Multiple System Atrophy Treatment.
- Multiple System Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Multiple System Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Multiple System Atrophy market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Multiple System Atrophy drugs and therapies
Multiple System Atrophy Pipeline Market Drivers
- Increased Awareness and Diagnosis, rising Genetic Research Activities are some of the important factors that are fueling the Multiple System Atrophy Market.
Multiple System Atrophy Pipeline Market Barriers
- However, ethical and Practical Challenges in clinical trials, lack of Early and Specific Diagnostic Biomarkers, poor Understanding of Disease Mechanism and other factors are creating obstacles in the Multiple System Atrophy Market growth.
Scope of Multiple System Atrophy Pipeline Drug Insight
- Coverage: Global
- Key Multiple System Atrophy Companies: Neuramedy Co.,Ltd, ProMIS Neurosciences, Enterin Inc., Nippon Chemiphar, CORESTEM, Inc, Brain Neurotherapy Bio, Inc., Kainos Medicines, Alterity Therapeutics, H. Lundbeck A/S, Biohaven, Ltd., Selecta Biosciences Inc, and others
- Key Multiple System Atrophy Therapies: NM-402, PMN442, ENT-01, NC-2500, CS10BR05, AAV2-GDNF, KM-819, ATH434, Lu AF82422, Verdiperstat, Ampreloxetine, and others
- Multiple System Atrophy Therapeutic Assessment: Multiple System Atrophy current marketed and Multiple System Atrophy emerging therapies
- Multiple System Atrophy Market Dynamics: Multiple System Atrophy market drivers and Multiple System Atrophy market barriers
Request for Sample PDF Report for Multiple System Atrophy Pipeline Assessment and clinical trials
Table of Contents
1. Multiple System Atrophy Report Introduction
2. Multiple System Atrophy Executive Summary
3. Multiple System Atrophy Overview
4. Multiple System Atrophy- Analytical Perspective In-depth Commercial Assessment
5. Multiple System Atrophy Pipeline Therapeutics
6. Multiple System Atrophy Late Stage Products (Phase II/III)
7. Multiple System Atrophy Mid Stage Products (Phase II)
8. Multiple System Atrophy Early Stage Products (Phase I)
9. Multiple System Atrophy Preclinical Stage Products
10. Multiple System Atrophy Therapeutics Assessment
11. Multiple System Atrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Multiple System Atrophy Key Companies
14. Multiple System Atrophy Key Products
15. Multiple System Atrophy Unmet Needs
16 . Multiple System Atrophy Market Drivers and Barriers
17. Multiple System Atrophy Future Perspectives and Conclusion
18. Multiple System Atrophy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 8774225362
Address:27 Drydock Ave S. Jones Blvd #2432
City: Boston
State: MA
Country: United States
Website: https://www.delveinsight.com/consulting/asset-prioritizaton-services